These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 2161034)

  • 41. [CMV infections].
    Pawłowska M; Halota W
    Przegl Epidemiol; 2004; 58 Suppl 1():17-21. PubMed ID: 15807153
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk factors for cytomegalovirus infection in BMT recipients transfused exclusively with seronegative blood products.
    Rubie H; Attal M; Campardou AM; Gayet-Mengelle C; Payen C; Sanguignol F; Calot JP; Charlet JP; Robert A; Huguet F
    Bone Marrow Transplant; 1993 Mar; 11(3):209-14. PubMed ID: 8385522
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The immunological underpinnings of vaccinations to prevent cytomegalovirus disease.
    McCormick AL; Mocarski ES
    Cell Mol Immunol; 2015 Mar; 12(2):170-9. PubMed ID: 25544503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Persistence of IgM antibodies to cytomegalovirus-induced late antigen in pregnancy and postpartum.
    Gärtner L; Kunkel M; Oberender H
    Acta Virol; 1983 Jan; 27(1):86-8. PubMed ID: 6133437
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Selection of particles and proteins for use as human cytomegalovirus subunit vaccines.
    Gibson W; Irmiere A
    Birth Defects Orig Artic Ser; 1984; 20(1):305-24. PubMed ID: 6329369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [The prevention of cytomegalovirus infection and disease by administration of biological products].
    Ihara T
    Nihon Rinsho; 1998 Jan; 56(1):145-50. PubMed ID: 9465680
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Transfusion support using filtered unscreened blood products for cytomegalovirus-negative allogeneic marrow transplant recipients.
    Narvios AB; Przepiorka D; Tarrand J; Chan KW; Champlin R; Lichtiger B
    Bone Marrow Transplant; 1998 Sep; 22(6):575-7. PubMed ID: 9758346
    [TBL] [Abstract][Full Text] [Related]  

  • 48. CMV vaccine shows impressive control in nonhuman primates.
    IAVI Rep; 2011; 15(3):19. PubMed ID: 21809803
    [No Abstract]   [Full Text] [Related]  

  • 49. Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease.
    Porath A; McNutt RA; Smiley LM; Weigle KA
    Rev Infect Dis; 1990; 12(1):31-40. PubMed ID: 2154028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Could a vaccine against immune-evading cytomegalovirus become a reality?
    Emery VC
    Expert Rev Vaccines; 2011 Aug; 10(8):1109-11. PubMed ID: 21854303
    [No Abstract]   [Full Text] [Related]  

  • 51. Vaccination for the prevention of maternal and fetal infection with guinea pig cytomegalovirus.
    Bia FJ; Griffith BP; Tarsio M; Hsiung GD
    J Infect Dis; 1980 Nov; 142(5):732-8. PubMed ID: 6257798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CMV vaccine: a response to criticism.
    Plotkin SA
    Hosp Pract; 1978 Sep; 13(9):18, 24. PubMed ID: 213369
    [No Abstract]   [Full Text] [Related]  

  • 53. Cytomegalovirus vaccine virus (Towne strain) does not induce latency.
    Plotkin SA; Huang ES
    J Infect Dis; 1985 Aug; 152(2):395-7. PubMed ID: 2993436
    [No Abstract]   [Full Text] [Related]  

  • 54. Immunisation trials with live attenuated cytomegalovirus TOWNE 125.
    Just M; Buergin-Wolff A; Emoedi G; Hernandez R
    Infection; 1975; 3(2):111-4. PubMed ID: 171221
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Trends in research in developing new type of vaccines--aiming at efficacy and safety. Cytomegalovirus vaccine].
    Furukawa T
    Nihon Rinsho; 1987 Oct; 45(10):2421-6. PubMed ID: 2834581
    [No Abstract]   [Full Text] [Related]  

  • 56. Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age.
    Adler SP; Starr SE; Plotkin SA; Hempfling SH; Buis J; Manning ML; Best AM
    J Infect Dis; 1995 Jan; 171(1):26-32. PubMed ID: 7798679
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge.
    Plotkin SA; Starr SE; Friedman HM; Gönczöl E; Weibel RE
    J Infect Dis; 1989 May; 159(5):860-5. PubMed ID: 2540247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Detection of antibody to cytomegalovirus early antigen in vaccinated, normal volunteers and renal transplant candidates.
    Friedman AD; Furukawa T; Plotkin SA
    J Infect Dis; 1982 Aug; 146(2):255-9. PubMed ID: 6286789
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cytomegalovirus vaccine.
    Plotkin SA
    Am Heart J; 1999 Nov; 138(5 Pt 2):S484-7. PubMed ID: 10539854
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cytomegalovirus vaccine. Specific humoral and cellular immune responses in human volunteers.
    Gehrz RC; Christianson WR; Linner KM; Groth KE; Balfour HH
    Arch Intern Med; 1980 Jul; 140(7):936-9. PubMed ID: 6247988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.